Subcutaneous nanotherapy repurposes the immunosuppressive mechanism of rapamycin to enhance allogeneic islet graft viability

Standard oral rapamycin (i.e. Rapamune®) administration is plagued by poor bioavailability and broad biodistribution. Thus, this pleotropic mTOR inhibitor has a narrow therapeutic window, numerous side effects and provides inadequate protection to transplanted cells and tissues. Furthermore, the hyd...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, Jacqueline A., Zhang, Xiaomin, Bobbala, Sharan, Frey, Molly A., Fuentes, Carolina Bohorquez, Haddad, Helena Freire, Allen, Sean D., Richardson, Reese A.K., Ameer, Guillermo A., Scott, Evan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934301/
https://www.ncbi.nlm.nih.gov/pubmed/35039683
http://dx.doi.org/10.1038/s41565-021-01048-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934301/
https://www.ncbi.nlm.nih.gov/pubmed/35039683
http://dx.doi.org/10.1038/s41565-021-01048-2

Ejemplares similares